NCT04928677: A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment |
|
|
| Recruiting | 1 | 50 | US | Codrituzumab | Memorial Sloan Kettering Cancer Center, Chugai Pharma USA | Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) | 06/25 | 06/25 | | |
